Involvement of the complement system in antibody-mediated post-exposure protection against human immunodeficiency virus type 1

AIDS Research and Human Retroviruses

Volumn 14, Issue 3, 1998, Pages 205-211

  Gauduin, Marie Claire ^a,b   Weir, Raymond ^a   Fung, Michael S C ^c   Koup, Richard A ^a,d  

^a ROCKEFELLER UNIVERSITY   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c Tanox Biosystems Inc   (United States)

^d UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COBROTOXIN; IMMUNOGLOBULIN FC FRAGMENT; MONOCLONAL ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; COMBINED IMMUNODEFICIENCY; COMPLEMENT ACTIVATION; COMPLEMENT INHIBITION; COMPLEMENT SYSTEM; CONTROLLED STUDY; HUMAN IMMUNODEFICIENCY VIRUS; MOUSE; NATURAL KILLER CELL; NONHUMAN; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; VIRUS INACTIVATION; VIRUS NEUTRALIZATION;

EID: 0032501948     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.1998.14.205     Document Type: Article

References (48)

1. Loofbourow JC, Cabasso VJ, Roby RE, and Anuskiewicz W: Rabies immune globulin (human). Clinical trials and dose determination. JAMA 1971;217:1825-1831.
2. Groothuis JR, Levin MJ, Rodriguez W, Hall CB, Long CE, Kim HW, Lauer BA, Hemming VG, and Group TRS: Use of intravenous gamma globulin to passively immunize high-risk children against respiratory syncytial virus: Safety and pharmacokinetics. Antimicrob Agents Chemother 1991;35:1469-1473.
3. Condie RM, Hall BL, Howard RJ, Fryd D, Simmons RL, and Najarian JS: Treatment of life-threatening infections in renal transplant recipients with high-dose intravenous human IgG. Transplant Proc 1979;11:66-68.
4. Warson S, Ahlmën J, Eriksson E, Hermodsson S, Kjellman H, Ljunggren C, and Selander D: Hepatitis B immune globulin in prevention of hepatitis B among hospital staff members. J Infect Dis 1977;135:473-477.
5. Seeff LB and Koff RS. Passive and active immunoprophylaxis of hepatitis B. Gastroenterology 1984;86:958-981.
6. Emini EA, Nara PL, Schleif WA, Lewis JA, Davide JP, Lee DR, Kessler J, Conley S, Matsushita S, Putney SD, et al.: Antibody-mediated in vitro neutralization of human immunodeficiency virus type 1 abolishes infectivity for chimpanzees. J Virol 1990;64: 3674-3678.
7. Emini EA, Schleif WA, Nunberg JH, Conley AJ, Eda Y, Tokiyoshi S, Putney SD, Matsushita S, Cobb KE, Jett CM, et al.: Prevention of HIV-1 infection in chimpanzees by gp120 V3 domain-specific monoclonal antibody. Nature (London) 1992;355:728-730.
8. Gauduin M-C, Safrit JT, Weir R, Fung MSC, and Koup RA: Pre-and postexposure protection against human immunodeficiency virus type 1 infection mediated by a monoclonal antibody. J Infect Dis 1995;171:1203-1209.
9. Safrit JT, Fung MSC, Andrews CA, Braun DG, Sun WNC, Chang TW, and Koup RA: Hu-PBL-SCID mice can be protected from HIV-1 infection by passive transfer of monoclonal antibody to the principal neutralizing determinant of the envelope gp120. AIDS 1993;7:15-21.
10. Haigwood NL, Watson A, Sutton WF, McClure J, Lewis A, Ranchalis J, Travis B, Voss G, Letvin NL, Hu SL, Hirsch VM, and Johnson PR: Passive immune globulin therapy in the SIV/macaque model: Early intervention can alter disease profile. Immunol Lett 1996;51:107-114.
11. Gunthard HF, Gowland P, Schupbach J, Fung MSC, Boni J, Liou RS, Chang NT, Grab P, Graepel P, Braun DG, and Luthy R: A phase I/IIA clinical study with chimeric mouse-human monoclonal antibody to the V3 loop of human immunodeficiency virus type 1 gp120. J Infect Dis 1994;170:1384-1393.
12. Jackson G, Perkins J, Rubenis M, Paul D, Knigge M, Despotes J, and Spencer P: Passive immunoneutralization of human immunodeficiency virus in patients with advanced AIDS. Lancet 1988;2:647-652.
13. Jacobson JM, Colman N, Ostrow NA, Simson RW, Tomesch D, Marlin L, Rao M, Mills JL, Clemens J, and Prince AM: Passive immunotherapy in the treatment of advanced human immunodeficiency virus infection. J Infect Dis 1993;168:298-305.
14. Karpas A, Hill F, Youle M, Cullen V, Gray J, Byron N, Hayhoe F, Tenant-Flowers M, Howard L, Gilgen D, Oates JK, Hawkins D, and Gazzard B: Effects of passive immunization in patients with the acquired immunodeficiency syndrome-related complex and acquired immunodeficiency syndrome. Proc Natl Acad Sci USA 1988;85:9234-9237.
15. Vittecoq D, Chevert S, Morand-Joubert L, Heshmati F, Audat F, Bary M, Dusautoir T, Bismuth A, Viard JP, Barré-Sinoussi F, Bach JF, and Lefrere JJ: Passive immunotherapy in AIDS: A double-blind randomized study based on transfusions of plasma rich in anti-human immunodeficiency virus 1 antibodies vs. transfusions of seronegative plasma. Proc Natl Acad Sci USA 1995;92:1195-1199.
16. Fung MSC, Sun C, Sun NC, Chang NT, and Chang TW: Monoclonal antibodies that neutralize HIV-1 virions and inhibit syncytium formation by infected cells. Bio/Technology 1987;5:940-946.
17. Liou RJ, Rosen EM, Fung MS, Sun WN, Sun C, Gordon W, Chang NT, and Chang TW: A chimeric mouse-human antibody that retains specificity for HIV gp120 and mediates the lysis of HIV-infected cells. J Immunol 1989;143:3967-3975.
18. Andrus L: Passive immunization against HIV-1 infection using HIV immune globulins (HIVIG). In: Retroviruses of Human AIDS and Related Animal Diseases (Girard M and Vallette L, eds.). Foundation Merieux, Paris, 1993, pp. 251-257.
19. Moore JP and Nara PL: The role of the V3 loop of gp120 in HIV infection. AIDS 1991;5:S21-S33.
20. Steimer KS, Scandella CJ, Skiles PV, and Haigwood NL: Neutralization of divergent HIV-1 isolates by conformation-dependent human antibodies to gp120. Science 1991;254:105-108.
21. Hanson CV, Crawford-Miksza L, and Sheppard HW: Application of a rapid microplaque assay for determination of human immunodeficiency virus neutralization antibody titers. J Clin Microbiol 1990;28:2030-2037.
22. Spear GT, Sullivan BL, Landay AL, and Lint TF: Neutralization of human immunodeficiency virus type 1 by complement occurs by virus lysis. J Virol 1990;64:5869-5873.
23. Hesselton RM, Koup RA, Cromwell MA, Graham BS, Johns M, and Sullivan JL: Human peripheral blood xenografts in the SCID mouse: Characterization of immunological reconstitution. J Infect Dis 1993;168:630-640.
24. Mosier DE, Gulizia RJ, Baird RS, and Wilson DB: Transfer of a functional human immune system to mice with severe combined immunodeficiency. Nature (London) 1988;335;256-259.
25. Fung MS, Sun CR, Liou RS, Gordon W, Chang NT, Chang TW, and Sun NC: Monoclonal anti-idiotypic antibody mimicking the principal neutralization site in HIV-1 GP120 induces HIV-1 neutralizing antibodies in rabbits. J Immunol 1990;145:2199-2206.
26. Dulbecco R: End-point method-measurement of the infectious titer of a viral sample. In: Virology, 2nd Ed. J.P. Lippincott, Philadelphia, 1988, pp. 22-25.
27. Ho DD, Moudgil T, and Alam M: Quantitation of human immunodeficiency virus type 1 in the blood of infected persons. N Engl J Med 1989;321:1621-1625.
28. Koup RA and Ho DD: Quantitative culture assay for HIV-1 in peripheral blood. In: Techniques in HIV Research (Aldovini A and Walker BD, eds.). Stockton Press, New York, 1990, pp. 107-112.
29. Ho DD, Fung MS, Cao YZ, Li XL, Sun C, Chang TW, and Sun NC: Another discontinuous epitope on glycoprotein gp120 that is important in human immunodeficiency virus type 1 neutralization is identified by a monoclonal antibody. Proc Natl Acad Sci USA 1991;88:8949-8952.
30. Ho DD, McKeating JA, Li XL, Moudgil T, Daar ES, Sun NC, and Robinson JE: Conformational epitope on gp120 important in CD4 binding and human immunodeficiency virus type 1 neutralization identified by a human monoclonal antibody. J Virol 1991;65:489-493.
31. Ho DD, Sarngadharan MG, Hirsch MS, Schooley RT, Rota TR, Kennedy RC, Chanh TC, and Sato V: Human immunodeficiency virus neutralizing antibodies recognize several conserved domains on the envelope glycoproteins. J Virol 1987;61:2024-2028.
32. Koup RA, Hesselton RM, Safrit JT, Somasundaran M, and Sullivan JL: Quantitative assessment of human immunodeficiency virus type 1 replication in human xenografts of acutely-infected Hu-PBL-SCID mice. AIDS Res Hum Retroviruses 1994;10:279-284.
33. Cooper NR and Nemerow GR: Complement and infectious agents: A Tale of disguise and deception. Complement Inflammation 1989;6:249-258.
34. Hirsch RL: The complement system: Its importance in the host response to viral infection. Microbiol Rev 1992;46:71-85.
35. Bosma GC, Custer RP, and Bosma MJ: A severe combined immunodeficiency mutation in the mouse. Nature (London) 1983;301:527-530.
36. Dorshkind KG, Keller M, Phillips RA, Miller RG, Bosma GC, O'Toole M, and Bosma MJ: Functional status of cells from lymphoid and myeloid tissues in mice with severe combined immunodeficiency disease. J Immunol 1984;132:1804-1808.
37. Schultz LD, Schweitzer PA, Christianson SW, Gott B, Schweitzer IB, Tennent B, McKenna S, Mobraaten L, Rajan TV, Greiner DL, and Leiter EH: Multiple defects in innate and adaptive immunologic function in NOD/LtSz-scid mice. J Immunol 1985;154: 180-191.
38. Van der berg CW, Aerts PC, and Van Dijk H: In vitro anticomplementary activities of the cobra venom factors from Naja naja and Naja haje. J Immunol 1991;136:287-294.
39. Pepys MB, Mirjah DD, and Wansbrough-Jones MH: Immunosuppression by cobra factor: Distribution, antigen-induced blast transformation and trapping of lymphocytes during in vivo complement depletion. Cellular Immunol 1976;21:327-336.
40. Cochrane CG, Muller-Eberhard HJ, and Aikin BS: Depletion of plasma complement in vivo by a protein of cobra venom: Its effect on various immunologic reactions. J Immunol 1970;105: 55-69.
41. Montefiori DC: Role of complement and Fc receptors in the pathogenesis of HIV-1 infection. Springer Semin Immunopathol 1997; 18:371-390.
42. Hosoi S, Borsos T, Dunlop N, and Nara P: Heat-labile, complement-like factor(s) of animal sera prevent(s) HIV-1 infectivity in vitro. J Acquir Immune Defic Syndr 1990;3:366-371.
43. Spear G, Sullivan B, Takefman D, Landay A, and Lint T: Human immunodeficiency virus (HIV)-infected cells and free virus directly activate the classical complement pathway in rabbit, mouse and guinea-pig sera; activation results in virus neutralization by virolysis. Immunology 1991;73:377-382.
44. Gauduin M-C, Parren PWHI, Weir R, Barbas CF, Burton DR, and Koup RA: Passive immunization with a potent neutralizing human monoclonal antibody protects hu-PBL-SCID mice against challenge by primary isolates of human immunodeficiency virus type 1. Nature Med 1997;3:1389-1393.
45. Langlois AJ, Weinhold KJ, Matthews TJ, Greenberg ML, and Bolognesi DP: Detection of anti-human cell antibodies in sera from macaques immunized with whole inactivated virus. AIDS Res Hum Retroviruses 1992;8:1641-1646.
46. Montefiori DC, Cornell RJ, Zhou JY, Zhou JT, Hirsch VM, and Johnson PR: Complement control proteins, CD46, CD55, and CD59, as common surface constituents of human and simian immunodeficiency viruses and possible targets for vaccine protection. Virology 1994;205:82-87.
47. Spear JT, Takefman DM, Sullivan BL, Landay AL, Jennings MB, and Carlson JR. Anticellular antibodies in sera from vaccinated macaques can induce complement-mediated virolysis of human immunodeficiency virus and simian immunodeficiency virus. Virology 1993;195:475-483.
48. Montefiori DC, Reiman KA, Letvin NL, Zhou J, and Hu SL: Studies of complement-activating antibodies in the SIV/macaque model of acute primary infection and vaccine protection. AIDS Res Hum Retroviruses 1995;11:963-970.